PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

Expert Opin Biol Ther. 2007 Apr;7(4):543-54. doi: 10.1517/14712598.7.4.543.


PANVAC is a cancer vaccine therapy delivered through two viral vectors--recombinant vaccinia and recombinant fowlpox--which are given sequentially. Both vectors contain transgenes for the tumor-associated antigens epithelial mucin 1 and carcinoembryonic antigen, which are altered or overexpressed in most carcinomas. The vectors also contain transgenes for three human T cell costimulatory molecules required to enhance immune response: B7.1, intracellular adhesion molecule-1 and leukocyte function-associated antigen-3. PANVAC is injected subcutaneously and processed by the body's antigen-presenting cells. Preclinical studies have demonstrated the efficacy of PANVAC in inducing both carcinoembryonic antigen- and mucin 1-specific cytotoxic T lymphocyte responses in vitro and in murine models. Other strategies that enhance the immune response include the use of granulocyte-macrophage colony-stimulating factor and a prime-boost administration sequence. Clinical trials have demonstrated PANVAC's safety and its ability to induce antigen-specific T cell responses. Early clinical trials are evaluating PANVAC alone and in combination with conventional chemotherapy and/or radiation. Studies to date hold promise for the use of PANVAC as a means to stimulate the immune system against malignancies and to provide clinical benefit.

Publication types

  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Cancer Vaccines* / immunology
  • Cancer Vaccines* / pharmacology
  • Cancer Vaccines* / therapeutic use
  • Carcinoembryonic Antigen / drug effects*
  • Carcinoembryonic Antigen / immunology
  • Carcinoembryonic Antigen / metabolism
  • Carcinoma* / drug therapy
  • Carcinoma* / immunology
  • Carcinoma* / metabolism
  • Clinical Trials as Topic
  • Humans
  • Membrane Glycoproteins* / immunology
  • Membrane Glycoproteins* / pharmacology
  • Membrane Glycoproteins* / therapeutic use
  • Mucin-1 / drug effects*
  • Mucin-1 / immunology
  • Mucin-1 / metabolism
  • Treatment Outcome


  • Cancer Vaccines
  • Carcinoembryonic Antigen
  • Membrane Glycoproteins
  • Mucin-1
  • Panvac-VF